Business Wire

Servify Enables Samsung Care+ for Business in Canada

14.6.2022 15:30:00 EEST | Business Wire | Press release

Share

Servify, a global AI-driven product ownership experience platform, announced its partnership with Samsung Electronics Canada to roll out its premium protection plan for corporate devices: Samsung Care+ for Business. The service is designed exclusively for nationwide enterprises and government customers.

After a successful launch last year in the US market where the Samsung B2B program has been well received, the partnership is now extending into the Canadian market which is poised to see more than 90 percent of Canadians becoming digital natives by 2023.*

As remote work went from “new normal” to “status quo” over the last two years, enterprises have witnessed an increased dependency on mobile devices for work and are concerned about business continuity challenges. To solve this, Samsung Care+ for Business is set to deliver a complete solution for device protection, thereby maximizing business productivity.

Servify will be responsible for overall management and administration of the program, together with system integration with Samsung’s authorized repair partners. Leveraging Servify’s post-sales product ownership experience platform, Samsung is poised to deliver protection with a combined coverage term of up to 3 years.**

Benefits for Enterprises

  • Digital and fully automated claims journey
  • Contract Management feature (customer can log-in and view details such as start/end date, coverage, covered device, etc.)
  • Bulk Claim upload feature

“We are thrilled to have partnered with Samsung for their B2B program in Canada. Our ongoing alliance with Samsung covers several regions including US, Eastern Europe, KSA, UAE and India which reiterates the trust Samsung has in our capabilities,” said Sreevathsa Prabhakar, Founder of Servify.

“Today’s businesses are making significant investments in devices, and we believe it is our job to help them be prepared for any issues with seamless, automated device management tools. Samsung Care+ for Business, enabled by Servify’s platform and underpinned by Samsung’s authorized repair services for physical damage and liquid intrusion protection, will prove beneficial for businesses as they need to anticipate when devices are reaching end-of-life, determine if they are vulnerable to security breaches, and resolve a host of other issues before such issues create operational delays,” said Steven Cull , Head of Mobile Product Management, Services and Strategy, at Samsung Canada.

Samsung Care+ for Business provides its customers a worry-free protection plan, guaranteed Samsung certified service and hassle-free process for claims and tech support.

* https://www.statista.com/topics/4865/internet-usage-in-canada/#dossierKeyfigures

** Manufacturer's limited warranty is 1 year, plus up to 2 years of extended warranty - for a total of up to 3 years warranty. Available on certain Samsung devices, including Galaxy XCover and Tab Active Series devices. For physical damage and liquid intrusion service requests, two (2) covered claims are allowed per each 12-month period during the duration of the Samsung Care+ for Business.

About Samsung

Samsung Electronics Canada inspires Canadians to reach their full potential through a transformative ecosystem of products and services that deliver innovation and distinct design to every aspect of their connected lives. The company is redefining the worlds of TVs, smartphones and wearable devices, tablets and digital appliances. In 2022, Samsung was ranked as one of Canada's "Most Reputable Companies" in Léger's Corporate Reputation Study. Dedicated to helping make a difference in the lives of Canadians, Samsung's award-winning corporate giving initiatives support public education and health-related issues in communities across the country. To discover more, please visit www.Samsung.ca.

About Servify

Servify integrates multiple OEM Brands and their sales and service ecosystem through its product lifecycle management platform, to deliver great after-sales service experience. Started in 2015, India Headquartered Servify has spread its reach in multiple countries across the globe, partnering with over 75 OEM brands including top mobile device brands, retailers, distributors, insurers, service providers and carriers. The Servify platform processes more than 3 million transactions monthly, with 250k+ Platform users spread across retailers, service centres, contact centres and administration teams worldwide serving millions of consumers.

Additional information on Servify is available at www.servify.tech.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Debapriya Ghosh Biswas
Director - Marketing
+91-9833086156; debapriya.g@servify.tech

Rethu Panicker
Senior Manager - Corporate Communications
+91-9867181043; rethu.p@servify.tech

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye